12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sofosbuvir: Phase III ongoing

Gilead said a DSMB recommended continuation of the open-label Phase III ION-1 trial of a once-daily, oral fixed-dose combination of 400 mg sofosbuvir plus 90 mg ledipasvir based on a review of safety data from the first 200 patients in all 4 treatment arms and SVR4 data from 100 patients in the 12-week treatment arms. ION-1 trial is evaluating the fixed-dose combination with or without ribavirin for 12 or 24 weeks in...

Read the full 336 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >